 |
市場調查報告書
商品編碼
1524228
氯雷他定市場 - 按劑型（片劑、膠囊、糖漿）、給藥途徑（口服、外用）、類型（品牌、學名藥）、配銷通路（醫院藥房、零售藥房、線上藥局）、全球預測（ 2024 - 2032）Loratadine Market - By Dosage Form (Tablets, Capsules, Syrups), Route of Administration (Oral, Topical), Type (Branded, Generis), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Global Forecast (2024 - 2032) |
||||||
在藥物配方進步和消費者意識提高的推動下，2024年至2032年全球氯雷他定市場將以2.8%的複合年成長率成長。藥物輸送和增強配方方面的創新正在提高氯雷他定的療效和患者依從性，使其成為緩解過敏的首選。此外，越來越多的消費者對過敏管理和非困倦抗組織胺的好處的教育正在推動產品需求。這些因素，加上有效的行銷策略，以及氯雷他定在不斷發展的製藥領域中日益成長的重要性，將有利於行業的成長。
氯雷他定市場分為劑型、給藥途徑、類型、配銷通路和地區。
從劑型來看，由於消費者對服用便利性和劑量準確性的偏好不斷提高，膠囊領域的行業規模將在 2024 年至 2032 年間大幅成長。膠囊提供方便的包裝和有效的抗組織胺遞送，同時滿足尋求緩解過敏的廣大用戶的需求。吸引醫療保健提供者和消費者的便攜性和貨架穩定性等屬性也將刺激產品需求。
根據配銷通路，到 2032 年，醫院藥房領域的氯雷他定行業將獲得可觀的收益，這得益於其在過敏等急性和慢性疾病藥物配藥方面的強大作用。龐大的患者群體和治療方案中抗組織胺的廣泛使用導致醫院對產品的高需求。隨著全球醫療保健設施和患者入院人數的增加，醫院藥房對於推動大部分氯雷他定銷售同時確保廣泛的可及性和分銷變得至關重要。
由於過敏和呼吸道疾病發生率的增加，2024年至2032年亞太地區氯雷他定產業佔有率將以顯著的複合年成長率擴大。快速的城市化、不斷增加的醫療保健支出以及不斷擴大的醫療保健服務範圍導致了更高的產品需求。此外，監管部門的批准和不斷成長的藥品投資正在推動該地區的市場成長。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 過敏性疾病的盛行率不斷增加
- 非處方 (OTC) 配方的可用性
- 增加氯雷他定組合的研發
- 產業陷阱與挑戰
- 潛在副作用的風險
- 與其他抗組織胺的競爭
- 成長動力
- 成長潛力分析
- 監管環境
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按劑型，2021 - 2032 年
- 主要趨勢
- 平板電腦
- 膠囊
- 糖漿
- 其他劑型
第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年
- 主要趨勢
- 口服
- 專題
第 7 章：市場估計與預測：按類型，2021 - 2032
- 主要趨勢
- 品牌化
- 泛型
第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥房
- 網路藥房
第 9 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Bayer AG
- Cadila Pharmaceuticals Limited
- Cipla Ltd.
- Lannett Company, Inc.
- Merck KGaA
- Morepen Laboratories Ltd
- Perrigo Company plc
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- Viatris Inc.
Global Loratadine Market will grow at 2.8% CAGR from 2024 to 2032, propelled by advancements in pharmaceutical formulations and increased consumer awareness. Innovations in drug delivery and enhanced formulations are improving the efficacy and patient compliance of loratadine, making it a preferred choice for allergy relief. Also, the growing consumer education about allergy management and the benefits of non-drowsy antihistamines are boosting the product demand. These factors, coupled with effective marketing strategies, and the growing importance of loratadine in the evolving pharmaceutical landscape will favor the industry growth.
The loratadine market is fragmented into dosage form, route of administration, type, distribution channel, and region.
By dosage form, the industry size from the capsules segment will experience a substantial surge between 2024 and 2032, fueled by rising consumer preference for ease of ingestion and dosage accuracy. Capsules offer convenient packaging and effective delivery of antihistamine while catering to a broad spectrum of users seeking allergy relief. Attributes like portability and shelf stability to appeal to both healthcare providers and consumers will also boost the product demand.
Based on distribution channel, the loratadine industry from the hospital pharmacy segment will capture sizable gains through 2032, driven by strong role in dispensing medications for acute and chronic conditions like allergies. The large patient base and extensive use of antihistamines in treatment protocols is contributing to high product demand in hospitals. With increasing healthcare facilities and patient admissions globally, hospital pharmacies have grown crucial for driving the majority of loratadine sales while ensuring widespread accessibility and distribution.
Asia Pacific loratadine industry share will expand at a noteworthy CAGR from 2024 to 2032, owing to increasing incidences of allergies and respiratory conditions. Rapid urbanization, rising healthcare expenditure, and expanding access to healthcare services are contributing to higher product demand. Moreover, regulatory approvals and growing investments in pharmaceuticals are bolstering the market growth in the region.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of allergic conditions
- 3.2.1.2 Availability of over-the-counter (OTC) formulations
- 3.2.1.3 Increasing R&D in loratadine combinations
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Risk of potential side-effects
- 3.2.2.2 Competition from other antihistamines
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Tablets
- 5.3 Capsules
- 5.4 Syrups
- 5.5 Other dosage forms
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Oral
- 6.3 Topical
Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Branded
- 7.3 Generics
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacy
- 8.3 Retail pharmacy
- 8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Bayer AG
- 10.2 Cadila Pharmaceuticals Limited
- 10.3 Cipla Ltd.
- 10.4 Lannett Company, Inc.
- 10.5 Merck KGaA
- 10.6 Morepen Laboratories Ltd
- 10.7 Perrigo Company plc
- 10.8 Pfizer Inc.
- 10.9 Sun Pharmaceutical Industries Limited
- 10.10 Viatris Inc.
